1. Home
  2. IMCC vs CDT Comparison

IMCC vs CDT Comparison

Compare IMCC & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IM Cannabis Corp.

IMCC

IM Cannabis Corp.

HOLD

Current Price

$0.38

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

SELL

Current Price

$3.53

Market Cap

2.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IMCC
CDT
Founded
1980
2019
Country
Israel
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IMCC
CDT
Price
$0.38
$3.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
196.3K
81.3K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$63.88
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.37
52 Week High
$7.12
$11.00

Technical Indicators

Market Signals
Indicator
IMCC
CDT
Relative Strength Index (RSI) 33.03 51.38
Support Level $0.30 $3.64
Resistance Level $1.55 $5.36
Average True Range (ATR) 0.06 1.32
MACD 0.02 -0.12
Stochastic Oscillator 35.43 13.08

Price Performance

Historical Comparison
IMCC
CDT

About IMCC IM Cannabis Corp.

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: